The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 1, 2016, Pages 43-52

  Mancini, Simona ^a   Minniti, Stefania ^a   Gregori, Maria ^a   Sancini, Giulio ^a   Cagnotto, Alfredo ^b   Couraud, Pierre Olivier ^c   Ordóñez Gutiérrez, Lara ^d   Wandosell, Francisco ^d   Salmona, Mario ^b   Re, Francesca ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c INSTITUT COCHIN   (France)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alzheimer disease; Liposomes; Nanoparticles; Sink effect; Amyloid oligomers

Indexed keywords

BLOOD; GLYCOPROTEINS; LIPOSOMES; MAMMALS; NANOPARTICLES; NEURODEGENERATIVE DISEASES; OLIGOMERS; PEPTIDES; PROTEINS;

ALZHEIMER DISEASE; AMYLOID PEPTIDES; BLOOD-BRAIN BARRIER; INCURABLE DISEASE; MULTI-FUNCTIONAL NANOPARTICLES; PHOSPHATIDIC ACIDS; SINK EFFECT; THERAPEUTIC STRATEGY;

DISEASES;

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E PHOSPHATIDIC ACID LIPOSOME; LIPOSOME; NANOPARTICLE; OLIGOMER; PHOSPHATIDIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; DRUG BINDING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOLAYER CULTURE; MOUSE; NONHUMAN; PROTEIN AGGREGATION; ULTRACENTRIFUGATION; CELL CULTURE; CHEMISTRY; FEASIBILITY STUDY; ISOLATION AND PURIFICATION; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BLOOD-BRAIN BARRIER; CELLS, CULTURED; FEASIBILITY STUDIES; HUMANS; NANOPARTICLES;

EID: 84957078663     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.09.003     Document Type: Article

References (33)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
2. Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer disease. Acta Neuropathol 2009, 118:103-113.
3. Rensink A.A., De Waal R.M., Kremer B., Verbeek M.M. Pathogenesis of cerebral amyloid angiopathy. Brain Res Rev 2003, 43:207-223.
4. Attems J., Jellinger K.A. The overlap between vascular disease and Alzheimer disease-lessons from pathology. BMC Med 2014, 12:206.
5. Herrmann N., Chau S.A., Kircanski I., Lanctôt K.L. Current and emerging drug treatment options for Alzheimer disease: a systematic review. Drugs 2011, 71:2031-2065.
6. Bana L., Minniti S., Salvati E., Sesana S., Zambelli V., Cagnotto A., et al. Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease. Nanomedicine 2014, 10:1583-1590.
7. Re F., Airoldi C., Zona C., Masserini M., La Ferla B., Quattrocchi N., et al. Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer disease. Curr Med Chem 2010, 17:2990-3006.
8. Matsuoka Y., Saito M., Lafrancois J., Saito M., Gaynor K., Olm V., et al. Novel therapeutic approach for the treatment of Alzheimer disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, 23:29-33.
9. Demattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 2001, 98:8850-8855.
10. Demattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer disease. Science 2002, 295:2264-2267.
11. Boche D., Denham N., Holmes C., Nicoll J.A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer disease pathogenesis. Acta Neuropathol 2010, 120:369-384.
12. Sehgal N., Gupta A., Valli R.K., Joshi S.D., Mills J.T., Hamel E., et al. Withania somnifera reverses Alzheimer disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 2012, 109:3510-3515.
13. Gobbi M., Re F., Canovi M., Beeg M., Gregori M., Sesana S., et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 2010, 31:6519-6529.
14. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., Ladu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277:32046-32053.
15. Gregori M., Cassina V., Brogioli D., Salerno D., De Kimpe L., Scheper W., et al. Stability of abeta (1-42) peptide fibrils as consequence of environmental modifications. Eur Biophys J 2010, 39:1613-1623.
16. Re F., Cambianica I., Sesana S., Salvati E., Cagnotto A., Salmona M., et al. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol 2010, 156:341-346.
17. Tai L.M., Reddy P.S., Lopez-Ramirez M.A., Davies H.A., Male D.K., Loughlin A.J., et al. Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, Hcmec/D3, restricts apical-to-basolateral permeability to rhodamine 123. Brain Res 2009, 1292:14-24.
18. Vu K., Weksler B., Romero I., Couraud P.O., Gelli A. Immortalized human brain endothelial cell line hCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by Cryptococcus neoformans. Eukaryot Cell 2009, 8:1803-1807.
19. Orlando A., Re F., Sesana S., Rivolta I., Panariti A., Brambilla D., et al. Effect of nanoparticles binding β-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages. Int J Nanomedicine 2013, 8:1335-1347.
20. Cecchelli R., Dehouck B., Descamps L., Fenart L., Buée-Scherrer V.V., Duhem C., et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev 1999, 36:165-178.
21. Ordóñez-Gutiérrez L., Re F., Bereczki E., Ioja E., Gregori M., Andersen A.J., et al. Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-β levels in APP/PS1 transgenic mice. Nanomedicine 2015, 11:421-430.
22. Balducci C., Mancini S., Minniti S., La Vitola P., Zotti M., Sancini G., et al. Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer disease mouse models. J Neurosci 2014, 34:14022-14031.
23. Steinerman J.R., Irizarry M., Scarmeas N., Raju S., Brandt J., Albert M., et al. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol 2008, 65:906-912.
24. Re F., Cambianica I., Zona C., Sesana S., Gregori M., Rigolio R., et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine 2011, 7:551-559.
25. Stine W.B., Dahlgren K.N., Krafft G.A., Ladu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003, 278:11612-11622.
26. Re F., Sesana S., Barbiroli A., Bonomi F., Cazzaniga E., Lonati E., et al. Prion protein structure is affected by pH-dependent interaction with membranes: a study in a model system. FEBS Lett 2008, 582:215-220.
27. Omidi Y., Campbell L., Barar J., Connel D., Akhtar S., Gumbleton M. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 2003, 990:95-112.
28. Bachmeier C., Mullan M., Paris D. Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Cytotechnology 2010, 62:519-529.
29. Mangas-Sanjuan V., González-Álvarez I., González-Álvarez M., Casabó V.G., Bermejo M. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier. Mol Pharm 2013, 10:3822-3831.
30. Pisani V., Stefani A., Pierantozzi M., Natoli S., Stanzione P., Franciotta D., et al. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation 2012, 9:188.
31. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J Neurochem 2004, 89:807-811.
32. Sagare A.P., Bell R.D., Zlokovic B.V. Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2.
33. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer disease and other disorders. Nat Rev Neurosci 2011, 12:723-738.